Skip to content

Clinical trials

Completed Phase 2/3 Attention Deficit Disorder with Hyperactivity trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Attention Deficit Disorder with Hyperactivity Phase: Phase 2/3 Status: Completed Clear all

17 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20052
20071
20081
20091
20101
20111
20121
20142
20151
20162
20211
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed17

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
New York State Psychiatric Institute3
Eli Lilly and Company2
Massachusetts General Hospital2
Aevi Genomic Medicine, LLC, a Cerecor company1
Alcobra Ltd.1
Kieran Cooley1
National Healthcare Group, Singapore1
Neurocentria, Inc.1
R. van Mourik1
RCSI & UCD Malaysia Campus1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Attention Deficit Disorder with Hyperactivity17
Cocaine-Related Disorders2
Autistic Disorder1
Opioid-Related Disorders1

Trials

Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.